Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11526 posts found.

Caribbean tunicate Ecteinascidia turbinata

NICE gives final no to PharmaMar’s Yondelis

April 27, 2011 Sales and Marketing NICE, PharmaMar, Yondelis, ovarian cancer

A lack of evidence and an unconvincing patient access scheme has seen PharmaMar fail to win NICE backing for its …
News

Bayer defends Yasmin against BMJ studies

April 26, 2011 Sales and Marketing Bayer, Yasmin, contraception

Bayer has rallied strongly behind its top-selling contraceptive brand Yasmin after two studies in the British Medical Journal questioned the …
News
Pfizer

Deaths reported in Pfizer arthritis trial

April 26, 2011 Research and Development, Sales and Marketing Pfizer, rheumatoid arthritis, tofacitinib

Four deaths have been reported in a late-stage study of Pfizer’s arthritis drug tofacitinib. Three of the deaths are thought …
News

Report sounds off-label prescribing warning

April 21, 2011 Sales and Marketing EAASM, off label

A pharma-backed group has warned that some ‘off-label’ prescribing is dangerous for patients. A report by the European Alliance for …
News

Trevor Smith to lead Takeda in Europe

April 21, 2011 Research and Development, Sales and Marketing appointment, research and development, sales and marketing

Trevor Smith has been appointed chief executive of Takeda Pharmaceuticals Europe. Smith brings more than 30 years of pharmaceutical experience …
Appointment

Eisai launches cancer drug Halaven in UK

April 20, 2011 Sales and Marketing Eisai, Halaven, breast cancer

Eisai’s sea sponge derived breast cancer drug Halaven has been launched in the UK following approval from European regulators a …
News

Warner Chilcott plans to axe 500 jobs in Europe

April 20, 2011 Manufacturing and Production, Research and Development, Sales and Marketing Warner Chilcott, pharma job cuts

Warner Chilcott is looking to cut 500 jobs from its European operations as it seeks to minimise the impact of …
News
Novartis Gilenya (fingolimod)

Oral MS drug Gilenya launched in the UK

April 19, 2011 Sales and Marketing Novartis, gilenya, multiple sclerosis

Gilenya has become the first oral multiple sclerosis drug to be launched in the UK. Gilenya (fingolimod) is licenced to …
News
Novartis' Afinitor (everolimus)

NICE unimpressed with Novartis’ patient access scheme

April 19, 2011 Sales and Marketing Afinitor, Kidney cancer, NICE, Novartis

Novartis has been dealt a blow by NICE after the cost-effectiveness body finally refused to recommend, on appeal, its kidney …
News
Arthritis drug Remicade

J&J and Merck reach compromise on arthritis drug rights

April 19, 2011 Sales and Marketing Johnson & Johnson, Merck & Co, Remicade, Simponi

Johnson & Johnson and Merck & Co have agreed to split the regional rights to arthritis drugs Remicade and Simponi …
News
Boehringer Ingelheim

Boehringer’s Pradaxa recommended for expanded European licence

April 18, 2011 Sales and Marketing Boehringer Ingelheim, CHMP, Pradaxa

Pradaxa is on course to expand its European licence with a recommendation from the CHMP for a new indication in …
News
knowledgepoint360_interphase_tim_mustill

Tim Mustill and Jenny Hepburn join InterPhase

April 18, 2011 Sales and Marketing appointment, sales and marketing

KnowledgePoint360 Group has appointed Tim Mustill and Jennifer Hepburn to key positions within its strategic consulting practice InterPhase. Tim has …
Appointment
Pfizer

Phase III boost for Pfizer’s oral arthritis drug

April 18, 2011 Research and Development, Sales and Marketing Pfizer, rheumatoid arthritis, tofacitinib

Pfizer’s rheumatoid arthritis treatment tofacitinib has induced clinical remission of the disease according to one-year data from a phase III …
News

VBP: a fait accompli or room for manoeuvre?

April 18, 2011 Sales and Marketing value-based pricing

The pharma industry is seeking a compromise on the UK’s proposed value- based pricing, which promises to revolutionise the country’s …
Feature
Genzyme's headquarters

Genzyme MS drug shines in head-to-head trial with Rebif

April 18, 2011 Research and Development, Sales and Marketing Genzyme, Lemtrada, Sanofi-Aventis, relapsing multiple sclerosis

Genzyme’s multiple sclerosis candidate Lemtrada has impressed in a new phase II head-to-head trial. Five years’ worth of mid-stage data …
News
The Gateway to Local Adoption Series

Latest content

China approves fruquintinib combination for kidney cancer

May 29, 2026

BIOTRONIK, Charité and GHCF launch digital cardiology partnership

May 28, 2026

Endometriosis study begins recruitment in UK hospitals

May 28, 2026

MHRA authorises donidalorsen for hereditary angioedema prevention

May 27, 2026

Partnership aims to expand early access to medicines

May 26, 2026